Description générale
Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits angiogenesis. It is used in the treatment of vascular eye diseases and in treatment protocols for some cancers.
INN
Bevacizumab
Type de médicament
Biological agent
Historique des statuts LME
Ajouté pour la première fois en 2013
(TRS
985)
pour
Age related macular degeneration
Demande refusée en 2025
(TRS
1064)
pour
Hepatocellular carcinoma of liver
Wikipédia
DrugBank
Recommandations
Section
Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations
- Parenteral > Locoregional injections > Intravitreal: 25 mg per mL
Indications
Section
Immunomodulators
- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion
Indications